Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9496 in Women With Estrogen Receptor Positive HER-2 Negative Advanced Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2017
At a glance
- Drugs AZD 9496 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 07 Nov 2016 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018.
- 07 Nov 2016 Planned primary completion date changed from 1 Feb 2018 to 1 Mar 2018.
- 12 Jul 2016 Status changed from recruiting to active, no longer recruiting.